DOMA Urges Strategic Review and Sale of Pacira BioSciences Amid Management Concerns

Urgent Call for Strategic Review at Pacira BioSciences

In a significant move that underscores rising tensions between shareholders and management, DOMA Perpetual Capital Management LLC, a major stakeholder in Pacira BioSciences, Inc., has formally urged the company's Board of Directors to initiate a sale process. DOMA, which holds a 6.8% stake in the biopharmaceutical firm, expresses deep concerns regarding what it perceives as severe mismanagement and ineffective strategic decisions that have led to underwhelming financial performance and diminishing shareholder returns. The investment firm’s letter, dated November 10, 2025, outlines a series of critical issues, including excessive spending and a troubling decline in product sales, prompting a call for immediate action.

The letter highlights specific areas of concern, notably the financial implications of the company's recent relocation of its headquarters. DOMA argues that this move has resulted in unnecessary cash burn and poor allocation of resources. Additionally, the firm points to the significant stock-based compensation for executives, projected to reach approximately 6% of Pacira's market capitalization in 2025, which alarmingly exceeds the firm’s entire operating income year-to-date. This juxtaposition raises red flags about the priorities of the management team, particularly as Zilretta, one of Pacira’s key products, experiences a year-over-year sales decline of 2% through Q3.

DOMA's criticism goes beyond financial metrics; it reflects a broader dissatisfaction with the company’s leadership and strategic direction. With tens of millions in executive compensation awarded despite lackluster performance, DOMA suggests that the current trajectory is untenable. The firm indicates a willingness to increase its stake if necessary changes are implemented, emphasizing the urgent need for the Board to consider a full sale of the company to safeguard investor interests. This call for action not only highlights the ongoing challenges Pacira faces but also signals a pivotal moment for the company as it grapples with shareholder expectations and its future direction.

In addition to DOMA's concerns, the broader context of Pacira's operational strategies raises questions about its long-term viability in the competitive biopharmaceutical landscape. As the company navigates these internal challenges, its ability to respond to shareholder demands for transparency and accountability will be crucial. The pressure from DOMA serves as a reminder of the importance of aligning management decisions with shareholder interests to foster sustainable growth and value creation.

As Pacira BioSciences contemplates its next steps, the dialogue initiated by DOMA underscores a critical juncture for the company, with implications that could resonate throughout the biopharmaceutical sector as stakeholders increasingly advocate for accountability and strategic realignment.